RxDoctor Payments Data

Alicia Schollmeyer

Family · Shreveport, LANPI 1275800344

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $11,576 of the $14,141 with a category attached, or 81.9%. It is spread thinly across 60 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $4,289 and has fallen 83.3% since, to $716 in 2025. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,141in general payments, 2019–2025

Across 491 payments — averaging $28.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$3K
  • Amgen$887
  • AstraZeneca$878
  • Myriad Genetic Laboratories, Inc.$601
  • Johnson & Johnson$596
  • Incyte Corporation$569
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$11,57682%
  • Education$1,0507%
  • Other$1,51511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis72$2,505
Amgen41$887
AstraZeneca(2 entities)29$878
Myriad Genetic Laboratories, Inc.7$601
Johnson & Johnson28$596
Incyte Corporation13$569
Astellas Pharma US Inc19$547
E.r. Squibb & Sons, L.L.C.17$443
Merck25$436
AbbVie19$401
Genentech USA, Inc.20$344
Daiichi Sankyo Inc.15$306
Pharmacyclics LLC, An Abbvie Company14$284
Regeneron Healthcare Solutions, Inc.7$280
Exelixis Inc.4$274
Eisai Inc.16$266
Lilly USA, LLC2$250
Gilead3$231
Sanofi7$215
Bayer6$213
Sun Pharmaceutical Industries Inc.9$212
Sobi, Inc6$212
Jazz Pharmaceuticals Inc.4$189
Ipsen Biopharmaceuticals, Inc4$188
GSK4$171
Bristol Myers Squibb9$169
Servier Pharmaceuticals LLC3$168
Seagen Inc.5$161
Takeda Pharmaceuticals U.S.A., Inc.6$150
Tempus AI, Inc2$147
Coherus Oncology, Inc.9$126
AVEO Pharmaceuticals, Inc.1$125
Blueprint Medicines Corporation1$125
Springworks Therapeutics, Inc.1$125
Pfizer7$116
G1 Therapeutics, Inc.1$100
Sanofi-aventis U.S. LLC1$100
EMD Serono, Inc.4$86
Pharmacosmos Therapeutics Inc.4$69
Pharmaessentia USA Corporation3$66
Taiho Oncology, Inc.2$66
Recordati_rare_diseases_inc.3$66
Dova Pharmaceuticals4$65
Karyopharm Therapeutics Inc.4$63
Stemline Therapeutics Inc.3$53
Aurinia Pharma U.S., Inc.2$52
Rigel Pharmaceuticals, Inc.3$43
Acrotech Biopharma Inc.2$38
ADC Therapeutics America, Inc.2$37
Beigene USA, Inc.2$37
Puma Biotechnology, Inc.3$36
Mirati Therapeutics, Inc.1$32
Progenics Pharmaceuticals, Inc.1$31
Sumitomo Pharma America, Inc.1$23
Genmab U.S., Inc.1$23
Shield Therapeutics Inc1$21
Evoke Pharma, Inc.1$18
CTI Biopharma Corp.1$18
AMAG Pharmaceuticals, Inc.1$16
Kyowa Kirin, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,141 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$403,141
Medicare patients
234
Services billed
23,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate15$246,818
XtandiEnzalutamide12$130,854
ProcritEpoetin Alfa14$37,108
EliquisApixaban20$13,733
Anastrozole23$667
Potassium Chloride11$361
Letrozole14$330
Ondansetron OdtOndansetron15$247
Levothyroxine Sodium12$180
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$167
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$143
Pantoprazole Sodium11$54
Prednisone11$42

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$569$246,81815 claims
Astellas Pharma US IncXtandi$547$130,85412 claims
Johnson & JohnsonProcrit$596$37,10814 claims
PfizerEliquis$116$13,73320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →